Get the latest news, insights, and market updates on BCAX (Bicara Therapeutics Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally well-tolerated safety profile Company plans to develop a loading and every-three-week maintenance regimen for ficerafusp alfa, pending regulatory alignment Company to host conference call and webcast on Friday, February 20, 2026 at 8:30 a.m. ET BOSTON, Feb. 19, 2026 (GLOBE NEWSWIRE Feb 19, 2026 - $BCAX
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on February 2, 2026 to two new employees under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 158,900 shares of Bicara’s common stock Feb 5, 2026 - $BCAX
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial
Bicara Therapeutics (NASDAQ:BCAX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its 2026 corporate outlook and highlight 2025 milestones centered on its lead clinical program, ficerafusp alfa, a bifunctional antibody designed to modulate the tumor microenviron Jan 13, 2026 - $BCAX
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 Anticipates multiple expansion cohort data readouts in 2026 to further characterize ficerafusp alfa’s profile in HPV-negative HNSCC and support potential expansion into other solid tumor types, including colorectal cancer Claire Mazumdar, PhD, MBA, Chief Jan 12, 2026 - $BCAX
Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions
Bicara Therapeutics (BCAX) just picked up a double dose of index recognition, joining both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index. This shift can quietly reshape demand dynamics for its shares. See our latest analysis for Bicara Therapeutics. The latest index inclusions come after a powerful 90 day share price return of 64.02 percent from a current share price of 17.55 dollars, even though the 1 year total shareholder return is still negative. This... Dec 24, 2025 - $BCAX
The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices
Bicara Therapeutics Inc. has recently been added to both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, marking its inclusion in two widely followed biotechnology benchmarks. This dual index entry can broaden Bicara’s visibility among institutional and index-tracking investors, potentially increasing liquidity and deepening market participation in the stock. Next, we’ll explore how Bicara’s new inclusion in major biotechnology indices may influence its... Dec 22, 2025 - $BCAX
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara’s Dec 15, 2025 - $BCAX
Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data
Bicara Therapeutics (BCAX) just put fresh clinical data in the spotlight, with a Phase 1b expansion cohort of ficerafusp alfa plus pembrolizumab in first line HPV negative head and neck cancer earning FDA Breakthrough Therapy status. See our latest analysis for Bicara Therapeutics. The market has been quick to respond, with a roughly 33% 1 month share price return and about 56% 3 month share price return pushing Bicara to 18.76 dollars. However, the 1 year total shareholder return is still... Dec 5, 2025 - $BCAX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple